While the cause of resistance to HER2-directed therapy in breast cancer has been broadly characterized, as highlighted above, to the best of our knowledge, mechanisms downstream of acquired resistance have been less systematically analyzed. This evidence concerns the gene ERBB2 and breast carcinoma.